Form 4: Arcutis Biotherapeutics Executive Sells Shares to Cover Tax Obligations

Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 13,206 shares of common stock on August 2, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On August 2, 2024, Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 13,206 shares of the company's common stock.
• The sale was executed to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units.
• The shares were sold at a weighted average price of $9.0191, with individual transactions ranging from $8.74 to $9.26.
• Following the transaction, Burnett directly owns 196,587 shares of Arcutis Biotherapeutics.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction appears to be a routine sale to cover tax obligations, executed under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook on the company's future.

Industry Context

Insider sales are a common occurrence, especially when related to tax obligations from vesting equity. It's important to consider the context of the sale, such as the existence of a pre-arranged trading plan, to understand its potential impact.

Stakeholder Impact

• The sale could have a minor impact on shareholders if it creates temporary downward pressure on the stock price, although the impact is likely to be minimal given the relatively small number of shares sold.

Key Dates